Virology tidbits: KSHV and autophagy: vFLIP, v-CyclinD, and v-Bcl2

As discussed in various posts before, viral proteins interfere with autophagy at various points to promote viral replication either by subverting the cellular autophagy machinery to form replication centers, to prevent the presentation of viral antigen via the MHC Class -I/-II complex, interfere with antiviral signalling or to prevent the degradation of viral proteins and thus increase viral replication. The localisation of viral proteins to the ER can induce ER stress and thus promote autophagy, thus counteracting or delaying apoptosis, whereas other viral proteins derived from the same virus inhibit the fusion with the lysosome or prevent the maturation of the autophagosome by various mechanisms including binding to Beclin-1. Deregulation of autophagy however is not limited to cells infected with viruses or bacteria but can also be observed in human cancers. In the context of infection of cells with oncogenic viruses, interference with the autophagy pathway has been documented for proteins derived from a variety of oncogenic viruses, including but not limited to proteins encoded by Human T-Cell Leukemia/Lymphoma Virus-1 (HTLV-1), JC virus (JCV), BK polyomavirus (BKPyV), Epstein-Barr virus (EBV), Kaposi’s Sarcoma-Associated Herpesvirus (KSHV), Hepatitis B virus (HBV), and Hepatitis C virus (HCV). Akin to the infection of cells with positive strand RNA viruses, the induction of autophagy can have positive effects (e.g. BKPyV) or negative effects (e.g. JCV) on viral replication. Since the expression of viral oncoprotein commonly also induces the DNA damage response and thus might promote autophagy via increasing the expression of pro-autophagy genes in a p53-dependent manner as discussed before, oncogenic viruses the regulation of autophagy might contribute to the transformation of cells both in vitro and in vivo.

Kaposi Sarcoma- Associated Herpesvirus (KSHV) - also known as Human Herpesvirus 8 (HHV8) - is the causative agent of Kaposi’s Sarcoma (KS), a cancer associated with prominent cutaneous lesions. Being a Herpesvirus, KSHV is a large dsDNA virus with genome of approx. 165 kb in size. An amorphous protein layer, the tegument, surrounds the capsid and a lipid envelope derived from the cellular plasma membrane. The genome itself encodes for a number of viral variants of cellular proteins including Cyclin D (v-Cyclin D), Flice inhibitory protein (v-FLIP), and Bcl-2 (v-Bcl2) as well as Latency-associated nuclear antigen (LANA) which has a p53 binding activity that are required for the transformation of primary spindle cells infected with KSHV into tumour cells.

v-Cyclin D and v-Bcl2

v-Cyclin D is a homologue of the cellular Cyclin D and as such forms an active holoenzyme with both Cyclin dependent kinases (CDK) -4 and -6. Unlike cellular Cyclin D however, v-Cyclin D also associates with CDK-2 and CDK-9 in addition to having a broader substrate range than cellular Cyclin D. Complexes of v-Cyclin D and CDK-6 are also refractory to Cip/Kip and INK4 families of Cyclin-dependent kinase inhibitors (CKIs). Consequently, v-Cyclin D has been demonstrated to increase DNA synthesis via phosphorylation of Orc1 and Cdc6 in tumour cell lines whilst inducing the DNA damage response via activation of the ATM-Chk2 pathway in hTERT immortalised and primary human dermal microvascular endothelial cells (HDMEC) as evidenced by increase in γH2AX and 53BP1 positive foci. Similar to HDMEC expressing H-Ras^V12 , the expression of induces either autophagy dependent apoptosis or an irreversible cell cycle arrest known as oncogene-induced senescence (OIS).

As discussed before the activation of p53 by various pathways, including ATM and ATR, induces the formation of the autophagosome by increasing the expression of several genes, including DRAM and Sestrin-1. In the case of KSHV v-Cyclin D, in TIME cells expressing v-Cyclin D, increased levels of DRAM and Sestrin-1 have been observed as well as increased levels of p53 phosphorylated at Ser-15, indicating that the expression of KSHV v-Cyclin D induces autophagy via activation of p53 by ATM but not ATR. Interestingly, the expression of LANA does not counteract v-Cyclin D induced autophagy, reflecting experimental data that only a small amount of LANA binds p53.

KSHV v-Cyclin D and autophagy: induction of OIS via DRAM-1 ?

Since the induction of autophagy by H-Ras^V12 has been linked to the induction of OIS, the expression of v-Cyclin D may also induce OIS by a similar mechanism. KSHV infected cells however do not display OIS, suggesting that the viral genome encodes proteins inhibiting autophagy. One of these proteins is v-Bcl2 which similar to cellular Bcl-2 binds Beclin-1 and thus prevents the formation of the phagophore. In the case of v-Bcl2 derived from the murine γ-Herpesvirus 68 (γHV68), a mutant variant of γHV68 which expresses a v-Bcl2 variant that does not bind Beclin-1 does not maintain a chronic infection in mice whereas a mutant unable to bind the pro-apoptotic Bak protein establishes chronic infections comparable to wt virus, indicating that the ability to inhibit autophagy is required to establish a chronic infection. In the case of KSHV v-Bcl2, cellular assays indicate that v-Bcl2 does not bind Bak but in vitro studies using purified proteins suggest that v-Bcl2 can bind Bak.

Inhibition of v-Cyclin D induced autophagy by v-Bcl2 and vFLIP prevents OIS

The importance of inhibiting autophagy in KSHV infected cells is further highlighted by data indicating that in HEK 293T cells infected with KSHV the viral replication and transcription activator (RTA) encoded by KSHV ORF 50 increases the expression of cellular Bcl-2 following KSHV reactivation; indeed in cells transfected with shRNA targeting cellular Bcl-2, increased apoptosis and decreased viral replication can be observed (if the formation of autophagosomes is decreased as well has not been investigated).If similar to EBV RTA the expression of other autophagy related genes is also induced remains to be seen.

v-FLIP

The viral Fas-associated death domain-like interleukin-1β (IL-1β)-converting enzyme-inhibitory protein (vFLIP) has been postulated to bind to caspase-8 -and thus prevent caspase-8/Fas mediated apoptosis- although the initial results could not be confirmed in transgenic mice expressing vFLIP. Instead, vFLIP has been shown to regulatory components of the IκB kinase signalosome (in particular NEMO and IKKαβγ), inducing the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis (cIAP)-1 and -2 as well as c-FLIP via NF-κB dependent signaling pathways inducing the expression of cytokines. Unlike cFLIP, binding of vFLIP to NEMO is independent of TRAF thus constitutively activating NF-κB signalling pathways.

Inducing autophagy of a lymphoma cell line positive for KSHV, BCBL-1, and HEK 293T cells expressing a KSHV-ΔvFLIP construct by Rapamycin treatment induces growth arrest and autophagy-induced apoptosis, which can be attenuated by transfection of Beclin-1 siRNA, indicating that the induction of autophagy by KSHV is indeed sufficient to induce apoptosis. Autophagy induced cell death however can also be prevented by transfection of plasmids allowing the expression of wt vFLIP or mutant vFLIP carrying a deletion of the Fas-Associated protein with Death Domain (FADD), indicating that the ability of vFLIP to bind caspase-8 is not required for preventing apoptosis. Human NIH 3T3 and HCT 116 cells or murine MEF expressing vFLIP derived from KSHV, Herpesvirus Saimiri (HSV), or Molluscum contagiosum virus (MCV) were able to prevent starvation induced autophagy and NIH 3T3 cells expressing an inducible Trex-BCBL-vFLIP plasmid reduced the formation of autophagosomes (as well as growth arrest and apoptosis) compared to cells expressing the Trex-BCBL plasmid following Rapamycin treatment, indicating that vFLIP indeed is sufficient to inhibit autophagy. When immunoprecipated, KSHV vFLIP was shown to bind Atg3 via an Atg3 binding domain, thus preventing the conversion of LC3-I to LC3-II; accordingly, the expression of vFLIP whilst not preventing the formation of LC3-I positive autophagic vesicles inhibits the formation of LC3-II positive autophagosomes. Taken together with v-Bcl2 however the expression of both proteins together should prevent the formation of autophagy-related vesicles.

Since the expression of KSHV v-Cyclin D induces autophagy -and thus OIS- as discussed above, the expression of both v-Bcl2 and vFLIP counteracts OIS, allowing increased cell proliferation. It should be noted however that preventing OIS also leads to a mitotic catastrophe and aberrant centrosome duplication, both which are common features of tumour cells and indeed can be observed in KSHV infected cells. Inhibiting autophagy however also inhibits the secretion of cytokines as well as preventing the expression of viral latent proteins. It should be noted that the ectopic expression of a DED1 alpha2-helix ten amino-acid (alpha2) peptide or a DED2 alpha4-helix twelve amino-acid (alpha4) peptide containing the vFLIP-Atg3 binding domain in KSHV infected cells induces autophagy and autophagy associated apoptosis probably by sequestering vFLIP, preventing the interaction of vFLIP with Atg3.

vFLIP and autophagy:inhibition via binding to ATG3

Recent data indicate that the inhibition of autophagy KSHV vFLIP in endothelial Long-Term-Infected Telomerase-Immortalized Endothelial Cells (TIVE-LTC), leads to an accumulation of Ser-403 phosphorylated p62/SQSTM-1 in the cytoplasm. As discussed before, Ser-403 phosphorylated p62/SQSTM-1 can induce the ubquitinylation of Keap1 and its degradation via the proteasome concomitant with stabilisation and clear translocation of Nrf2. Indeed, vFLIP induces the nuclear translation of Nrf2 in TIVE-LTC cells as well as induction of genes related to angiogenesis, inflammation, and the antioxidant response. In TIVE-LTC the stabilisation of Nrf2 is increased via vFLIP mediated activation of PKCζ via cycloxygenase-2 (COX-2)/PGE-2 mediated signalling pathways. It remains to be seen however if the expression of the vFLIP-Atg3 binding domain can reverse the increase of Nrf2 by stimulating p62/SQSTM-1 dependent selective autophagy.

KSHV vFLIP and degradation of Keap1 via increased levels of p62/SQSTM-1 and
PKCζ

v-Cyclin D, v-Bcl2, vFLIP are however not the only KSHV proteins interfering with autophagy. Proteins which induce the formation of the phagophore include the K1, vIL-6, and a viral G protein coupled receptor (vGPCR) of KSHV, all of which activate the Phosphoinositide 3kinase (PI3K)– AKT–mTORC1 pathway and the ORF45 protein has been shown to contribute to the activation of mTORC1 in lymphatic endothelial cells by activating the ERK2–RSK1–TSC2 pathway. KSHV K7 inhibits the maturation of autophagosomes by binding Rubicon thus preventing the fusion of the autophagosome with the lysosome.

The expression of K7, vBcl-2 and vFLIP therefore is central to the ability of KSHV to evade antiviral signalling pathways whilst maintaining signalling required for cellular survival and proliferation.

Another viral protein, ORF 57, has been shown to increase the expression of X-linked inhibitor of apoptosis (XIAP). Interestingly, XIAP has been linked to autophagy inhibition via degradation of Mdm2 and stabilization of p53 in serum starved MEF, which has been linked to increased tumourgenesis in mice. The question remains if this is also true for cells –murine or human- expressing KSHV or the murine γHV68. Interestingly, the expression of Rhesus monkey rhadinovirus (RRV) derived vFLIP in Hela as well as in RRV infected BJAB cells inhibits apoptosis whilst increasing the formation of LC3-II positive autophagosomes. So far however a smilier effect has not been reported in cells derived from rabbits.

KSHV and autophagy: summary

Recent studies involving drugs such as Sirolimus which activate autophagy by binding mTOR and thus inhibiting the mTOR kinase highlighted the importance of autophagy inhibition in KSHV infected cells, delaying IL-6, IL-10, and IFN-γ dependent tumourgenesis.

Virology tidbits

Virology tidbits

Thursday, 15 January 2015

KSHV and autophagy: vFLIP, v-CyclinD, and v-Bcl2

No comments:

Post a Comment